Your session is about to expire
← Back to Search
TH1902 for Cancer
Study Summary
This trial is testing a new drug, TH1902, in cancer patients who have few other treatment options. The first part of the trial is to find the best dose of the drug, and the second part is to test it in patients with specific types of cancer that are known to express a protein called SORT1.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your ECG shows a specific measurement called QTc that is longer than 470 milliseconds.You have any of the following blood-related issues before starting the study.I have chronic HBV, a history of HCV, or am on HCV treatment.My ovarian cancer is high grade and not responding to standard treatments.I haven't had cancer treatments or experimental drugs in the last 4 weeks.I have an eye condition.I am 18 years old or older.I agree to use effective birth control methods during and after treatment as required.I do not have any major health issues that could affect my safety or interfere with the study.My cancer is resistant to standard treatments.I have recovered from previous treatment side effects, except for mild nerve issues or hair loss.I have had 8 or fewer previous cancer treatments.You have certain abnormal blood test results at the beginning of the study.Your kidneys do not filter blood well, with a clearance of less than 50 mL/min.I have recovered from side effects of previous treatments, except for mild hair loss.I don't have active brain metastases or spinal issues that could affect my treatment.I agree to use highly effective birth control methods if I'm sexually active.I do not have active brain cancer or spinal issues but can join if my brain cancer has been stable for 4 weeks without steroids.I am 18 years old or older.It looks like there might be a mistake here. It seems like the criterion "Part 4" may be incomplete or missing information. If you provide more details or context, I'd be happy to help you summarize it.I am fully active or can carry out light work.I am allergic to taxanes or ingredients in the TH1902 drug.My cancer got worse while on or within 6 months after finishing a taxane-based treatment.You are expected to live for at least 3 more months.You have a disease that can be measured using a specific method called RECIST 1.1.I am fully active or restricted in physically strenuous activity but can do light work.I have ongoing eye problems from treatment that are moderate to severe.I need frequent procedures to remove excess fluid from my abdomen.I had severe side effects from taxane-based treatment.I have not received a live vaccine in the last 30 days.I do not have significant nerve damage or muscle weakness.I haven't had a serious infection needing IV treatment in the last 14 days.I have ongoing nerve damage symptoms that are moderate or severe.I haven't taken drugs that affect liver enzymes in the last 14 days.It seems like there might be a mistake, as "Part 3" doesn't provide enough context to rewrite the criterion for clarity. If you can provide more details or the specific criterion you'd like to have rewritten, I'd be happy to help.My advanced cancer does not respond to standard treatments.I have recovered from side effects of previous treatments, except for mild hair loss.You have a specific amount of disease that can be measured using a standard guideline.People with HIV, Hepatitis B, or Hepatitis C can join the study if they meet certain conditions.I haven't had treatments for advanced lung cancer, but past treatments for early-stage cancer ended over a year ago.My CD4+ T-cell count is 350 or higher.My cancer is not responding to standard treatments and TH1902 could be an option.I have had 8 or fewer cancer treatments in total.You are capable of understanding and have voluntarily signed the informed consent document and willing to comply with study requirements.
- Group 1: TH1902
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What have been the reported outcomes of TH1902 treatments on patients?
"There is minimal evidence that TH1902 is safe and effective, hence it was awarded a score of 1."
How many participants are there in this experimental research?
"This medical research requires the involvement of 70 patients that adhere to the inclusion criteria. Notably, eligible individuals can partake in this study at START Midwest situated in Grand Rapids, Michigan or at University of Texas MD Anderson Cancer Center based in Houston, Pennsylvania."
Is this particular clinical study still open to further participants?
"As per the documentation on clinicaltrials.gov, this medical trial is now recruiting participants. It was initially launched in March 2021 and updated as recently as June 2022."
What is the current count of medical sites executing this clinical trial?
"This clinical trial is currently being conducted in 6 different cities, with Grand Rapids, Houston and Gettysburg constituting 3 of the locations. Therefore it is advised that patients select a clinic nearest to them so they can reduce their travel costs if they decide to join this study."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger